BMJ Open Diabetes Research & Care

Glucagon-like peptide-1 receptor agonists for primary cardiovascular disease prevention in type 2 diabetes, a systematic review

By Guillaume Grenet, Raha Eskandari, Joyce Ko, Wade Thompson

Figure 1. Flow chart. — Figure 1. Flow chart.Flow chart.Grenet et al.

Meta-analysis of randomised trialsInterventions

Declared ties to: French

The paper

Guillaume Grenet, Raha Eskandari, Joyce Ko, Wade Thompson

University of British Columbia

BMJ Open Diabetes Research & Care, 19 Aug 2026

doi.org/10.1136/bmjdrc-2026-006225 PubMed 42618306

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Cardiology and Therapy4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes